Nazartinib; EGF816; NWS-816

Lub npe tshuaj:

(R,E)-N-(7-chloro-1-(1-(4-(dimethylamino)but-2-enoyl)azepan-3-yl)-1H-benzo[d]imidazol-2-yl)- 2-methylisonicotinamide

SMILES Code:

O=C(NC1=NC2=CC=CC(Cl)=C2N1[C@H]3CN(C(/C=C/CN(C)C)=O)CCCC3)C4=CC=NC(C)= C4

InChi Code:

InChI = 1S/C26H31ClN6O2/c1-18-16-19(12-13-28-18)25(35)30-26-29-22-10-6-9-21(27)24(22)33( 26) 20-8-4-5-15-32(17-20)23(34)11-7-14-31(2)3/h6-7,9-13,16,20H,4-5, 8,14-15,17H2,1-3H3,(H,29,30,35)/b11-7+/t20-/m1/s1

InChi Key:

IOMMMLWIABWRKL-WUTDNEBXSA-N

Lo lus tseem ceeb:

Nazartinib EGF816, EGF-816, EGF 816, NVS-816, 1508250-71-2

Solubility:Soluble hauv DMSO

Cia:0 - 4 ° C rau lub sijhawm luv (hnub mus rau lub lis piam), lossis -20 ° C rau lub sijhawm ntev (hli)

Nqe lus piav qhia:

Nazartinib, tseem hu ua EGF816 thiab NVS-816, yog ib qho kev hais lus muaj, irreversible, thib peb tiam, mutant-selective epidermal growth factor receptor (EGFR) inhibitor, muaj peev xwm ua haujlwm antineoplastic. EGF816 covalently khi rau thiab inhibits cov kev ua ntawm mutant daim ntawv ntawm EGFR, nrog rau cov T790M EGFR mutant, yog li tiv thaiv EGFR-mediated signaling. Qhov no yuav ua rau ob qho tib si ua rau cov cell tuag thiab inhibit qog loj hlob hauv EGFR-overexpressing qog hlwb. EGF816 nyiam inhibits cov ntaub ntawv hloov pauv ntawm EGFR suav nrog T790M, qhov thib ob tau txais kev hloov pauv hloov pauv, thiab tuaj yeem muaj txiaj ntsig kho mob hauv cov qog nrog T790M-kho tawm tsis kam thaum piv rau lwm yam EGFR tyrosine kinase inhibitors.

Hom phiaj: EGFR